Prolonged course of pure red cell aplasia after erythropoietin therapy

Nigg, Luzia; Schanz, Urs; Ambühl, Patrice M.; Fehr, Jörg; Bächli, Esther

doi:10.1111/j.1600-0609.2004.00317.x

Cited by 8 publications

(8 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the 19 PRCA patients who received a renal transplant and subsequent administration of cyclosporine or tacrolimus, transfusion independence was obtained by all patients except 1 (95%). 17 Among 89 nontransplantation PRCA patients who received immunosuppressive therapies without transplantation, 49% achieved a hematologic recovery. Country-specific hematologic recovery rates ranged from 31% for patients in Spain to 100% for patients in Singapore.…”

Section: Resultsmentioning

confidence: 99%

Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project

Bennett¹,

Cournoyer²,

Carson³

et al. 2005

Blood

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project

Bennett¹,

Cournoyer²,

Carson³

et al. 2005

Blood

View full text Add to dashboard Cite

show abstract

“…However, packed RBCs may be indicated in patients who experience a sudden and significant drop in Hb to below 10 g/dl, or in those with hemolysis but higher Hb levels who have signs or symptoms suggestive of myocardial or cerebral ischemia. Transfusion or packed RBCs, as well as alternate fluid administration and correction of any existing coagulopathy, is also indicated for the immediate treatment of significant bleeding in patients with chronic hepatitis C, regardless of etiology (50).…”

Section: Transfusion Therapymentioning

confidence: 99%

Definition and management of anemia in patients infected with hepatitis C virus

McHutchison

Manns

Longo

2006

Liver International

View full text Add to dashboard Cite

Chronic infection with hepatitis C virus (HCV) can progress to cirrhosis, hepatocellular carcinoma, and end-stage liver disease. The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin. Although this regimen produces sustained virologic responses (SVRs) in approximately 50% of patients, it can be associated with a potentially dose-limiting hemolytic anemia. Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders. In general, anemia can increase the risk of morbidity and mortality, and may have negative effects on cerebral function and quality of life. Although ribavirin-associated anemia can be reversed by dose reduction or discontinuation, this approach compromises outcomes by significantly decreasing SVR rates. Recombinant human erythropoietin has been used to manage ribavirin-associated anemia but has other potential disadvantages. Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.

show abstract

“…Recombinant human erythropoietin is uncommonly associated with some adverse effects: thrombosis, hypertension and pure red blood cell aplasia [86–88]. However, no serious rHuEPO‐related events occurred in the study by Sulkowski et al [84].…”

Section: Other Therapeutic Considerations In Coinfected Patientsmentioning

confidence: 99%

Therapeutic issues in HIV/HCV‐coinfected patients

Sulkowski

Benhamou

2006

Journal of Viral Hepatitis

View full text Add to dashboard Cite

Summary. The importance of treating hepatitis C virus (HCV)‐associated morbidities in a growing population of patients coinfected with human immunodeficiency virus (HIV) has increased since the introduction of highly active antiretroviral therapy. As a result, investigative attention is turning to HCV‐related liver disease and treatment‐associated issues in coinfection. HIV/HCV‐coinfected patients have higher HCV RNA loads and show more rapid progression of fibrosis than do monoinfected patients. Combination therapy with pegylated interferon plus ribavirin (RBV) is the standard of care for HCV in coinfected patients. Therapy slows fibrosis progression, but toxicity prevents identification of the most effective RBV dose. Coinfected patients have about a threefold greater risk of antiretroviral therapy‐associated hepatotoxicity than patients with HIV only. Other challenges include anaemia, mitochondrial toxicity, drug–drug interactions and leucopenia. Thus, chronic hepatitis C should be treated in HIV/HCV‐coinfected patients, but steps must be taken to prevent and treat potential toxicities. The first European Consensus Conference on the Treatment of Chronic Hepatitis B and C in HIV Co‐infected Patients was held March 2005 in Paris to address these issues. This article reviews the peer‐reviewed literature and expert opinion published from 1990 to 2005, and compares results with presentations and recommendations from the Consensus Conference to best present current issues in coinfection.

show abstract

Prolonged course of pure red cell aplasia after erythropoietin therapy

Cited by 8 publications

References 13 publications

Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project

Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project

Definition and management of anemia in patients infected with hepatitis C virus

Therapeutic issues in HIV/HCV‐coinfected patients

Contact Info

Product

Resources

About